Business
OPSYH: Opsy acquisition marks a decisive shift from biotech to insuretech SaaS focus
OPSYH: Opsy acquisition marks a decisive shift from biotech to insuretech SaaS focus
About this update from Opsy Holding Ab
Foxy-5 failed in phase 2, prompting a strategic pivot to acquire Opsy AB, an insuretech firm, via a reverse takeover. The deal, if approved, shifts focus to SaaS for insurance claims; otherwise, liquidation is likely. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.